Carfilzomib

The FDA approved isatuximab-irfc for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who previously received one to three prior lines of therapy.

The FDA approved daratumumab for use combined with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, according to a press release.

Once weekly selinexor, carfilzomib and dexamethasone showed an overall response rate of 72% in patients with relapsed/refractory multiple myeloma who have received a median of four lines of prior therapy, according to data presented at ASCO20 Virtual Scientific Program.

ORLANDO — In this video, Matthew Pianko, MD, clinical assistant professor of internal medicine at the University of Michigan’s Rogel Cancer Center, discusses a late breaking abstract on the “exciting” CANDOR study presented the ASH Annual Meeting and Exposition.

ORLANDO — A novel triple-agent combination of carfilzomib, dexamethasone and daratumumab outperformed carfilzomib plus dexamethasone in terms of PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to results of the randomized phase 3 CANDOR trial presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.

ORLANDO — Patients with multiple myeloma treated with carfilzomib demonstrated a significantly higher relative risk for serious infections, particularly respiratory tract infections, compared with those on other treatments, according to a study presented at the ASH Annual Meeting and Exposition.